Description

Mifortik (Mycophenolate Sodium) Enteric Tablets 180 mg. №120

Recommended dosage: The usual dose is 720 mg twice daily. Dosage may vary based on individual patient needs.

Mifortik (Mycophenolate Sodium) Enteric Tablets are indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants.

Do not use Mifortik (Mycophenolate Sodium) Enteric Tablets if you are allergic to mycophenolate sodium or any other ingredients in the product.

Take Mifortik (Mycophenolate Sodium) Enteric Tablets exactly as prescribed by your healthcare provider. Swallow the tablets whole with water, do not crush or chew them.

Mycophenolate sodium is a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase, a crucial enzyme for the de novo synthesis of guanosine nucleotides. This action suppresses T-lymphocyte and B-lymphocyte proliferation, reducing the immune response against transplanted organs.
Clinical trials have demonstrated the efficacy of mycophenolate sodium in preventing organ rejection in transplant recipients. A study by Nashan et al. (2009) showed that mycophenolate sodium was well-tolerated and effective in renal transplant patients, with a low incidence of acute rejection episodes.

It is important to follow your healthcare provider’s instructions carefully while taking Mifortik (Mycophenolate Sodium) Enteric Tablets. Inform your doctor about any other medications you are taking to avoid potential drug interactions.
Contact your healthcare provider immediately if you experience any unusual symptoms or side effects while using Mifortik (Mycophenolate Sodium) Enteric Tablets.